Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
2021 Year in Review - Multiple Myeloma
2021 Year in Review: Advances in Dual IO Cancer Treatments
2021 Year in Review - Breast Cancer
2021 Oncology Drug Coding and Updates
2021 Year in Review - Renal-Cell Carcinoma
2021 Year in Review - Ovarian Cancer
2021 Year in Review - Gastrointestinal Cancer
2021 Year in Review - Non–Small-Cell Lung Cancer
2021 Year in Review - Biosimilars
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2021 Novel Oncology Drug Approvals
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
ASH 2021 - AML
ASH 2021 - Myelofibrosis
2021 Myelofibrosis Wrap-Up
AACR & ASCO 2021 - Midyear Review
ASCO 2021 - Lung Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Issues
2018
September 2018, Vol 8, No 9
September 2018, Vol 8, No 9
Cannabis for Symptom Management in Cancer: Do You Know What Your Patients Are Using?
By
Meg Barbor, MPH
Medicinal Cannabis
,
Symptom Management
Patients with cancer are increasingly using cannabinoids (the chemical component of cannabis) to treat many symptoms, and a minority of them even take cannabis as a treatment for the cancer itself. Recent surveys have revealed that up to 25% of patients with cancer take some form of cannabis, but oncologists and other medical providers are often unaware that their patients are using medical (or recreational) cannabis.
Read More ›
Dispelling Misconceptions About HCC Coding
By
Karyn M. Dyehouse, MD
Coding and Billing
,
Reimbursement
Oncologists are operating in a whole new world as healthcare transitions to value-based care. To thrive in this emerging environment, providers must understand the many details involved in how value-based models work.
Read More ›
MSI-H a Marker for Lynch Syndrome, a More Common Condition Than Generally Expected
By
Wayne Kuznar
Biomarkers
Tumors with high microsatellite instability (MSI-H) are predictive of Lynch syndrome. The recent approval of the first immunotherapies for use in patients with MSI-H or with mismatch repair-deficiency (dMMR) in solid tumors is now leading to routine testing for MSI-H or dMMR in patients with advanced solid tumors.
Read More ›
Managing Cancer-Related Fatigue and Insomnia in Patients and Caregivers
By
Meg Barbor, MPH
Symptom Management
Cancer-related fatigue and insomnia frequently co-occur among patients with cancer, and emerging data have demonstrated that caregivers of patients with cancer also have a high symptom burden, with elevated rates of depression, sleep disturbance, and fatigue
Read More ›
Building on the Successes of Cancer Immunotherapy
By
Charles Bankhead
Immunotherapy
Learning how to activate and harness the immune system—the body’s built-in defense against disease—has brought the field of oncology to the cusp of a cure for at least some, if not many, types of cancer, according to an international authority in immuno-oncology.
Read More ›
Timing of Palliative Care Consults Key in Elderly Patients with Pancreatic Cancer
By
Chase Doyle
Palliative Care
A claims analysis of elderly patients with pancreatic cancer has shown that those receiving early palliative care consultations had lower healthcare utilization than patients who received late palliative care.
Read More ›
Best Practices: Evolving Understanding of Molecular Diagnostics and Biomarkers in Lung Cancer
By
Geoff Oxnard, MD
;
Lauren Ritterhouse, MD, PhD
2018 ASCO Highlights
,
Biomarkers
,
Interview with the Innovators
At ASCO 2018,
Oncology Practice Management
(
OPM
) discussed the current state of genetics and genomic testing, the increasing understanding of biomarkers, and how they influence the treatment of patients with lung cancer.
Read More ›
Selective RET Inhibitor, BLU-667, Hits the Target in Patients with Lung or Thyroid Cancers
By
Phoebe Starr
Emerging Therapies
A novel oral agent (BLU-667) that targets
RET
genetic alterations, achieved durable disease control and was safe in patients with lung or thyroid cancers and
RET
mutations, as demonstrated by the first-in-human phase 1 clinical trial ARROW.
Read More ›
TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition
By
Phoebe Starr
Emerging Therapies
,
Immunotherapy
A novel approach using the investigational toll-like receptor 9 (TLR9) agonist CMP-001 in combination with pembrolizumab (Keytruda) may have the potential to reverse resistance to anti–PD-1 therapy, according to data from a preliminary phase 1b clinical trial.
Read More ›
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
2022 Midyear Review: Non–Small-Cell Lung Cancer
2.
New Policies Regarding Intravenous Iron Replacement Are Creating Conundrum for Providers and Payers
By
Dawn Holcombe, MBA, FACMPE, ACHE
3.
Oncology Guide to Patient Support Services Index
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
2021 Year in Review - Multiple Myeloma
2021 Year in Review: Advances in Dual IO Cancer Treatments
2021 Year in Review - Breast Cancer
2021 Oncology Drug Coding and Updates
2021 Year in Review - Renal-Cell Carcinoma
2021 Year in Review - Ovarian Cancer
2021 Year in Review - Gastrointestinal Cancer
2021 Year in Review - Non–Small-Cell Lung Cancer
2021 Year in Review - Biosimilars
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2021 Novel Oncology Drug Approvals
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
ASH 2021 - AML
ASH 2021 - Myelofibrosis
2021 Myelofibrosis Wrap-Up
AACR & ASCO 2021 - Midyear Review
ASCO 2021 - Lung Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
OPM
Print Edition
OPM
Weekly e‑Newsletter
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
OPM
's
Privacy Policy
, and
OPM
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION